In order for thelatest drug reform efforts to have a real impact, plans will likelyhave to be able to restrict the access that senior citizens havehad for more than a decade to certain classes of drugs. (Photo:Shutterstock)
President Donald Trump's drug pricing-push is about to run into whatmight be its most potent opponent yet: America's seniorcitizens.
On Monday afternoon, the Trump administration released a proposal for rules that would makeit easier for Medicare Part D prescription-drug plans to negotiate prices for a broader array ofmedicines than they do currently. That's arguably a good thing. Butin order for this effort to have a real impact, plans will likelyhave to be able to restrict the access that senior citizens havehad for more than a decade to certain classes of drugs.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
